2017
DOI: 10.1101/cshperspect.a030452
|View full text |Cite
|
Sign up to set email alerts
|

Androgen Signaling in Prostate Cancer

Abstract: The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand the mechanisms behind CRPC have revealed new insights into dysregulated androgen signaling and intratumoral androgen syn… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
256
0
4

Year Published

2017
2017
2024
2024

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 316 publications
(286 citation statements)
references
References 199 publications
(181 reference statements)
3
256
0
4
Order By: Relevance
“…Among them, salivary duct carcinoma is the most frequent AR-expressing cancer, ranging from 64 to 98% of the cases. Excessive activation of AR signaling is strongly associated with the prognosis and malignancy of cancers in the salivary glands, prostate and breast (Dai et al, 2017;Giovannelli et al, 2018;Robinson et al, 2015). Interestingly, several studies indicate that expression of NRF2 and NRF1 is associated with prostate cancers via AR transactivation in humans and mice (Frohlich et al, 2008;Schultz et al, 2014).…”
Section: Discussionmentioning
confidence: 99%
“…Among them, salivary duct carcinoma is the most frequent AR-expressing cancer, ranging from 64 to 98% of the cases. Excessive activation of AR signaling is strongly associated with the prognosis and malignancy of cancers in the salivary glands, prostate and breast (Dai et al, 2017;Giovannelli et al, 2018;Robinson et al, 2015). Interestingly, several studies indicate that expression of NRF2 and NRF1 is associated with prostate cancers via AR transactivation in humans and mice (Frohlich et al, 2008;Schultz et al, 2014).…”
Section: Discussionmentioning
confidence: 99%
“…Amplification of the AR gene locus or point mutations in the AR gene occurs in 60% of tumors that have been subjected to androgen ablation therapy (3). The appearance of ligand-independent AR splice variants or AR posttranslational modification may also contribute to continued AR activation following castration (4). Other common genetic alterations in AR-expressing CRPC include heterozygous deletions of PTEN and, to a lesser extent, p53 inactivation or loss of Rb1 expression (5)(6)(7)(8).…”
Section: Introductionmentioning
confidence: 99%
“…Metastatic prostate cancer generally responds to androgen deprivation therapy (i.e., medical or surgical castration) but the tumor eventually progresses as castration-resistant prostate cancer (CRPC), which develops by way of tumor synthesis of testosterone and/or dihydrotestosterone (DHT) and other mechanisms that stimulate the androgen receptor (AR)(Attard et al, 2015; Dai, In press; Watson et al, 2015). Abiraterone and enzalutamide are 2 next-generation hormonal therapies that have a profound effect on metastatic disease, prolong survival and are FDA-approved for treatment of CRPC.…”
Section: Introductionmentioning
confidence: 99%